• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

表型可塑性耐药慢性髓性白血病细胞系在斑马鱼异种移植模型中表现出增强的细胞动力学。

Phenotypically plastic drug-resistant chronic myeloid leukaemia cell line displays enhanced cellular dynamics in a zebrafish xenograft model.

机构信息

Department of Molecular Biology and Genetics, Izmir Institute of Technology, Gulbahce, Urla, Izmir, Turkey.

Izmir Biomedicine and Genome Center (IBG), Dokuz Eylul University Health Campus, Izmir, İnciralti, Turkey.

出版信息

J Cell Mol Med. 2024 Oct;28(19):e70105. doi: 10.1111/jcmm.70105.

DOI:10.1111/jcmm.70105
PMID:39392217
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11467800/
Abstract

Understanding the mechanisms by which cancer cells switch between different adaptive states and evade therapeutic interventions is essential for clinical management. In this study, the in vivo cellular dynamics of a new chronic myeloid leukaemia cell line displaying altered phenotype and resistance to tyrosine kinase inhibitors were investigated in correlation with their parental cells for invasiveness/metastasis, angiogenic potential and population kinetics. We showed that the cells exhibiting drug resistance and plastic phenotype possess an increased capacity for invasion compared to their parental cells, that exposure to imatinib mesylate has the potential to enhance cellular motility and that in a leukaemic cell population, even a minority of plastic cells exhibit improved migratory ability. Furthermore, we show that these plastic cells have angiogenic and extravasation potential. The present study provides significant insights into the cellular dynamics displayed by a TKI-resistant, phenotypically plastic CML cell line, using a zebrafish (Danio rerio) xenograft model.

摘要

了解癌细胞在不同适应状态之间切换并逃避治疗干预的机制对于临床管理至关重要。在这项研究中,研究了一种新的慢性髓系白血病细胞系在体内的细胞动力学,该细胞系表现出改变的表型和对酪氨酸激酶抑制剂的耐药性,并与它们的亲本细胞进行了相关性研究,以研究其侵袭/转移、血管生成潜力和群体动力学。我们表明,与亲本细胞相比,表现出耐药性和可塑性表型的细胞具有更高的侵袭能力,暴露于甲磺酸伊马替尼有可能增强细胞迁移能力,并且在白血病细胞群体中,即使是少数可塑性细胞也表现出增强的迁移能力。此外,我们表明这些可塑性细胞具有血管生成和渗出潜力。本研究使用斑马鱼(Danio rerio)异种移植模型,深入了解了一种 TKI 耐药、表型可塑性 CML 细胞系的细胞动力学。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/74d5/11467800/d0c25ecacd0d/JCMM-28-e70105-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/74d5/11467800/a63c040b5287/JCMM-28-e70105-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/74d5/11467800/1f1dd4d7e379/JCMM-28-e70105-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/74d5/11467800/5ef73803409d/JCMM-28-e70105-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/74d5/11467800/d0c25ecacd0d/JCMM-28-e70105-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/74d5/11467800/a63c040b5287/JCMM-28-e70105-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/74d5/11467800/1f1dd4d7e379/JCMM-28-e70105-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/74d5/11467800/5ef73803409d/JCMM-28-e70105-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/74d5/11467800/d0c25ecacd0d/JCMM-28-e70105-g002.jpg

相似文献

1
Phenotypically plastic drug-resistant chronic myeloid leukaemia cell line displays enhanced cellular dynamics in a zebrafish xenograft model.表型可塑性耐药慢性髓性白血病细胞系在斑马鱼异种移植模型中表现出增强的细胞动力学。
J Cell Mol Med. 2024 Oct;28(19):e70105. doi: 10.1111/jcmm.70105.
2
Carboxyamidotriazole-orotate inhibits the growth of imatinib-resistant chronic myeloid leukaemia cells and modulates exosomes-stimulated angiogenesis.羧基氨三唑-乳清酸盐抑制伊马替尼耐药慢性髓系白血病细胞的生长并调节外泌体刺激的血管生成。
PLoS One. 2012;7(8):e42310. doi: 10.1371/journal.pone.0042310. Epub 2012 Aug 3.
3
Discovery of a highly potent kinase inhibitor capable of overcoming multiple imatinib-resistant ABL mutants for chronic myeloid leukemia (CML).发现一种高效的激酶抑制剂,能够克服多种伊马替尼耐药 ABL 突变体,用于治疗慢性髓性白血病(CML)。
Eur J Pharmacol. 2021 Apr 15;897:173944. doi: 10.1016/j.ejphar.2021.173944. Epub 2021 Feb 11.
4
The HDAC6 inhibitor 7b induces BCR-ABL ubiquitination and downregulation and synergizes with imatinib to trigger apoptosis in chronic myeloid leukemia.组蛋白去乙酰化酶 6 抑制剂 7b 诱导 BCR-ABL 泛素化和下调,并与伊马替尼协同作用,引发慢性髓性白血病细胞凋亡。
Pharmacol Res. 2020 Oct;160:105058. doi: 10.1016/j.phrs.2020.105058. Epub 2020 Jun 30.
5
Characterization of imatinib-resistant K562 cell line displaying resistance mechanisms.显示耐药机制的伊马替尼耐药K562细胞系的特征分析
Cell Mol Biol (Noisy-le-grand). 2018 May 15;64(6):23-30.
6
Cholesterol esterification inhibition and imatinib treatment synergistically inhibit growth of BCR-ABL mutation-independent resistant chronic myelogenous leukemia.胆固醇酯化抑制与伊马替尼治疗协同抑制BCR-ABL突变非依赖性耐药慢性粒细胞白血病的生长。
PLoS One. 2017 Jul 18;12(7):e0179558. doi: 10.1371/journal.pone.0179558. eCollection 2017.
7
A molecular and biophysical comparison of macromolecular changes in imatinib-sensitive and imatinib-resistant K562 cells exposed to ponatinib.对暴露于波纳替尼的伊马替尼敏感和伊马替尼耐药K562细胞中大分子变化的分子和生物物理比较
Tumour Biol. 2016 Feb;37(2):2365-78. doi: 10.1007/s13277-015-4015-9. Epub 2015 Sep 15.
8
Cryptotanshinone enhances the efficacy of Bcr-Abl tyrosine kinase inhibitors via inhibiting STAT3 and eIF4E signalling pathways in chronic myeloid leukaemia.隐丹参酮通过抑制慢性髓性白血病中的 STAT3 和 eIF4E 信号通路增强 Bcr-Abl 酪氨酸激酶抑制剂的疗效。
Pharm Biol. 2021 Dec;59(1):893-903. doi: 10.1080/13880209.2021.1944224.
9
Inhibition of protein kinase CK2 by CX-5011 counteracts imatinib-resistance preventing rpS6 phosphorylation in chronic myeloid leukaemia cells: new combined therapeutic strategies.CX-5011对蛋白激酶CK2的抑制作用可抵消伊马替尼耐药性,防止慢性粒细胞白血病细胞中的rpS6磷酸化:新的联合治疗策略。
Oncotarget. 2016 Apr 5;7(14):18204-18. doi: 10.18632/oncotarget.7569.
10
Targeting Hedgehog signaling pathway and autophagy overcomes drug resistance of BCR-ABL-positive chronic myeloid leukemia.靶向刺猬信号通路和自噬可克服BCR-ABL阳性慢性髓性白血病的耐药性。
Autophagy. 2015;11(2):355-72. doi: 10.4161/15548627.2014.994368.

本文引用的文献

1
Understanding and leveraging phenotypic plasticity during metastasis formation.理解并利用转移形成过程中的表型可塑性。
NPJ Syst Biol Appl. 2023 Oct 6;9(1):48. doi: 10.1038/s41540-023-00309-1.
2
Phenotypic plasticity promotes lymph nodes metastasis and drug resistance in lung squamous cell carcinomas.表型可塑性促进肺鳞状细胞癌的淋巴结转移和耐药性。
Heliyon. 2023 Mar 17;9(4):e14614. doi: 10.1016/j.heliyon.2023.e14614. eCollection 2023 Apr.
3
The Tumor Microenvironment in Tumorigenesis and Therapy Resistance Revisited.肿瘤发生与治疗抗性中的肿瘤微环境再探讨
Cancers (Basel). 2023 Jan 6;15(2):376. doi: 10.3390/cancers15020376.
4
Tumor Microenvironment-A Short Review of Cellular and Interaction Diversity.肿瘤微环境——细胞与相互作用多样性的简短综述
Biology (Basel). 2022 Jun 18;11(6):929. doi: 10.3390/biology11060929.
5
Cancer stem cells, plasticity, and drug resistance.癌症干细胞、可塑性与耐药性。
Cancer Drug Resist. 2020 Feb 21;3(2):140-148. doi: 10.20517/cdr.2019.112. eCollection 2020.
6
Cell plasticity in cancer cell populations.癌细胞群体中的细胞可塑性。
F1000Res. 2020 Jun 22;9. doi: 10.12688/f1000research.24803.1. eCollection 2020.
7
Tumor microenvironment complexity and therapeutic implications at a glance.肿瘤微环境的复杂性及其治疗意义简述。
Cell Commun Signal. 2020 Apr 7;18(1):59. doi: 10.1186/s12964-020-0530-4.
8
Zebrafish patient avatars in cancer biology and precision cancer therapy.斑马鱼患者生物信息学模型在癌症生物学和精准肿瘤治疗中的应用
Nat Rev Cancer. 2020 May;20(5):263-273. doi: 10.1038/s41568-020-0252-3. Epub 2020 Apr 6.
9
Adaptive phenotypic modulations lead to therapy resistance in chronic myeloid leukemia cells.适应性表型调节导致慢性髓性白血病细胞的治疗耐药性。
PLoS One. 2020 Feb 27;15(2):e0229104. doi: 10.1371/journal.pone.0229104. eCollection 2020.
10
Zebrafish Avatars towards Personalized Medicine-A Comparative Review between Avatar Models.斑马鱼虚拟人在个性化医学中的应用——虚拟人模型的比较综述
Cells. 2020 Jan 25;9(2):293. doi: 10.3390/cells9020293.